<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02719951</url>
  </required_header>
  <id_info>
    <org_study_id>PRIA 14 FBB / TANGAU</org_study_id>
    <nct_id>NCT02719951</nct_id>
  </id_info>
  <brief_title>Glutaminergic Transmission in Autism : Molecular Imaging Exploration</brief_title>
  <acronym>TANGAU</acronym>
  <official_title>Glutaminergic Transmission in Autism : Molecular Imaging Exploration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glutamatergic transmission exploration using PET (Positron Emission Tomography) imaging in&#xD;
      autism compared to Fragile-X Syndrome ( FXS) and Healthy Volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">November 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cerebral glutaminergic activity assessed by binding potential of [18F]FPEB</measure>
    <time_frame>An average of 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>distribution volume of [18F]FPEB</measure>
    <time_frame>An average of 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Autism</condition>
  <condition>Fragile-X Syndrome (FXS)</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>autistic patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[18F]FPEB PET imaging MRI (Magnetic Resonance Imaging) Biological samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FXS patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[18F]FPEB PET imaging MRI Biological samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[18F]FPEB PET imaging MRI Biological samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]FPEB PET imaging</intervention_name>
    <description>PET exam</description>
    <arm_group_label>FXS patients</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>autistic patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological samples</intervention_name>
    <description>blood sample and urine sample</description>
    <arm_group_label>FXS patients</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>autistic patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI exam</description>
    <arm_group_label>FXS patients</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>autistic patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Between 18 years-old and 45 years-old&#xD;
&#xD;
          -  Informed, written consent obtained from patient or his representant&#xD;
&#xD;
          -  Subject with an affiliation to French social security&#xD;
&#xD;
          -  For autistic patient : patient with diagnosis of ASD (Autistic Spectrum Disorders)&#xD;
             following DSM-IV or DSM-5 criteria with recommended tools (ADI-R and/or ADOS)&#xD;
&#xD;
          -  For FXS patient : diagnosis of FXS and confirmation of total mutation of FMR1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to MRI&#xD;
&#xD;
          -  Excessive use of alcohol or drug, or addiction to alcohol or drug during last 6 months&#xD;
&#xD;
          -  Any unstable or uncontrolled disease, clinically significant&#xD;
&#xD;
          -  Participation to an other experimental protocol with drug or irradiant exam&#xD;
&#xD;
          -  Person under exclusion period because of previous participation to an other&#xD;
             experimental protocol&#xD;
&#xD;
          -  Person under temporary guardianship&#xD;
&#xD;
          -  Forbidden treatments : any psychotropic treatment for 4 last weeks before PET exam and&#xD;
             changing durably glutaminergic transmission directly or undirectly&#xD;
&#xD;
          -  For healthy subjects : adult under guardianship, medical history of central nervous&#xD;
             system disease, medical history of attention deficit hyperactivity disorder, past or&#xD;
             present psychiatric or neurologic disorder (MINI DSM-IV)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2016</study_first_posted>
  <last_update_submitted>June 6, 2019</last_update_submitted>
  <last_update_submitted_qc>June 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autism</keyword>
  <keyword>fragile X syndrome (FXS)</keyword>
  <keyword>PET (Positron Emission Tomography)</keyword>
  <keyword>glutamate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fragile X Syndrome</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

